Search Results

PetVivo Holdings, Inc., a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal year ended March 31, 2024.

PetVivo Holdings, Inc. announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates into the joints of cats.

PetVivo Holdings, Inc. announces financial results for the three months ended September 30, 2023.

PetVivo Holdings, Inc. an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s proprietary biocompatible protein-based particles.

PetVivo Holdings, Inc., an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the third quarter of fiscal 2023.

PetVivo Holdings, Inc., an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, will report financial results for the year ending March 31, 2022, on Wednesday, June 29, 2022 after market close.

Medpace Holdings, Inc. announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024.